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Increasing prevalence of asthma diagnosis and
symptoms in children is confined to mild symptoms
G Ng Man Kwong, A Proctor, C Billings, R Duggan, C Das, M K B Whyte, C V E Powell,
R Primhak
Abstract
Background—The prevalence of childhood
asthma is increasing but few studies have
investigated trends in asthma severity. We
investigated trends in asthma diagnosis and
symptom morbidity between an eight year
time period in a paired prevalence study.
Methods—All children in one single school
year aged 8–9 years in the city of SheYeld
were given a parent respondent question-
naire in 1991 and 1999 based on questions
from the International Survey of Asthma
and Allergy in Children (ISAAC). Data
were obtained regarding the prevalence of
asthma and wheeze and current (12
month) prevalences of wheeze attacks,
speech limiting wheeze, nocturnal cough
and wheeze, and exertional symptoms.
Results—The response rates in 1991 and
1999 were 4580/5321 (85.3%) and 5011/6021
(83.2%), respectively. There were signifi-
cant increases between the two surveys in
the prevalence of asthma ever (19.9% v
29.7%, mean diVerence 11.9%, 95% confi-
dence interval (CI) 10.16 to 13.57, p<0.001),
current asthma (10.3% v 13.0%, mean
diVerence 2.7%, 95% CI 1.44 to 4.03,
p<0.001), wheeze ever (30.3% v 35.8%,
mean diVerence 5.7%, 95% CI 3.76 to 7.56,
p<0.001), wheeze in the previous 12 months
(17.0% v 19.4%, mean diVerence 2.5, 95%
CI 0.95 to 4.07, p<0.01), and reporting of
medication use (16.9% v 20%, mean diVer-
ence 3.0%, 95% CI 1.46 to 4.62, p<0.001).
There were also significant increases in
reported hayfever and eczema diagnoses.
Conclusions—Diagnostic labelling of
asthma and lifetime prevalence of wheeze
has increased. The current 12 month point
prevalence of wheeze has increased but
this is confined to occasional symptoms.
The increased medication rate may be
responsible for the static prevalence of
severe asthma symptoms. The significant
proportion of children receiving medi-
cation but reporting no asthma symptoms
identified from our 1999 survey suggests
that some children are being inappropri-
ately treated or overtreated.
(Thorax 2001;56:312–314)
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Childhood asthma is common, especially in the
UK.1 Several studies have reported increases in
the prevalence of asthma and associated
asthma morbidity symptoms using serial ques-
tionnaire surveys,2–7 but there has been contro-
versy as to whether or not the prevalence of
asthma is still increasing. The International
Study of Asthma and Allergies in Childhood
(ISAAC) questionnaire has been validated and
has been used to investigate the prevalence of
asthma throughout the world.1 We used a par-
ent respondent questionnaire based on the
ISAAC questions to investigate changes in
asthma morbidity and treatment between 1991
and 1999 in two large cohorts of SheYeld chil-
dren aged 8– 9 years.
Methods
The methods for the 1991 survey have been
described previously8 and were replicated in
the 1999 study. Briefly, all primary schools in
SheYeld with year 4 pupils (aged 8–9 years)
were approached for the 1999 survey. Individu-
ally labelled questionnaires were distributed to
schools with instructions for children to take
them home for their parents to complete. Non-
responders were sent a second identical
questionnaire. The ÷2 test was used to compare
the diVerences between the surveys. The study
was approved by the South SheYeld Research
Ethics Committee and the SheYeld Education
Authority.
Results
The results of the 1991 SheYeld schools
survey have been reported previously.8 A total
of 5011 of 6021 questionnaires (83.2%) were
returned from the 1999 survey. Of all responses
where sex was specified, 2459 of 4912 (50.1%)
were male. 156 of 5011 respondents (3.1%)
indicated that they did not wish to take part in
the survey. 4340 questionnaires were returned
with all 15 questions completed (354 and 66
returned questionnaires had 14 of the 15 and
13 of the 15 questions completed respectively;
a further 253 had fewer than 13 questions
completed). Wherever possible answers from
part completed questionnaires were included
in the data analysis.
Symptoms reported in the preceding 12
months in the two surveys are compared in
table 1. Although there were significant
increases in the prevalence of wheeze and in
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asthma diagnosis, the increase was confined to
wheeze <3 times yearly; more frequent symp-
toms were unchanged. Current wheeze, life-
time wheeze, current asthma (defined by a
positive answer to the question “Does your
child have asthma at present?”), and lifetime
asthma were significantly higher in boys than in
girls (21.4% v 17.4% (p<0.001), 38.8% v
33.0% (p<0.001), 14.0% v 12.0% (p<0.01),
and 32.6% v 27.1% (p<0.001), respectively).
Overall, in the 1999 survey 939 of 4700 chil-
dren (20.0%) were reported to be taking asthma
medication compared with 768 of 4533 children
(16.9%) in 1991 (mean diVerence 3.0%, 95%
confidence interval (CI) 1.46 to 4.62, p<0.001).
Medication details for children with diagnosed
asthma were available in 422 children in 1991
and 487 in 1999. Between surveys inhaled
corticosteroid usage increased from 34.4% to
66.1% (p<0.001), inhaled bronchodilator usage
increased from 79.6% to 92.8% (p<0.001), and
sodium cromoglycate usage decreased from
23.2% to 3.7% (p<0.001). Notably, in the 1999
survey we found that 249 of 931 children
(26.7%) receiving asthma medication reported
no wheezing in the last 12 months; even in those
taking regular inhaled corticosteroids this figure
was 19.4%. A further 192 (20.6%) children
receiving asthma medication were reported not
to have a current diagnosis of asthma.
Discussion
We have shown increases in the prevalences of
reported wheeze, diagnosed asthma, and re-
ported eczema and hayfever in 8–9 year old
SheYeld children between 1991 and 1999.
The point prevalence of wheeze in the past 12
months increased by an absolute value of 2.4%
over 8 years. This increase could be due to
methodological or response variations, changes
in parental or doctor behaviour, in either label-
ling or treatment, or a genuine change in
inherent susceptibility or in environmental fac-
tors. We have used consistent methodology and
achieved good response rates, so it is unlikely
that these diVerences could be due to diVer-
ences in methodology or population character-
istics. Similarly, the response rates of 85.3% in
1991 and 83.3% in 1999 suggest that any bias
due to non-responders is minimal.
Our observations are supported by a number
of previous studies.2–7 Burr et al studied two
cohorts of 12 year old children using question-
naire and exercise provocation tests 15 years
apart between 1973 and 1988.2 The point
prevalence of “wheeze ever” increased from
17% to 22% and “current asthma” from 4% to
9%. Between 1964 and 1989 asthma in
Aberdeen school children increased from 4.1%
to 10.1%4 and a repeat survey in 1994 reported
a further rise to 19.6% with, in contrast to our
study, an increase in asthma severity.6 Venn et al
reported cross sectional survey data between
1988 and 1995 which showed absolute in-
creases in lifetime and 12 month wheeze
prevalences and diagnosed asthma in children
aged 4–11 years.7 These studies have suggested
that the asthma prevalence rate has continued
to rise and that this cannot be ascribed solely to
diagnostic labelling, in contrast to the observa-
tions of Hill et al.3 Magnus and Jaakkola
consider that information biases and changes
in diagnostic labelling might explain the
increases in wheeze and asthma seen in other
repeated surveys and have suggested that
“objective measures” should be used.9 Since we
have previously shown that the free running
exercise test had much poorer reproducibility
than questionnaire data,10 we decided not to
include such a measure in our initial survey.
Our results suggest that the increase in
wheezing is largely due to infrequent and
minor wheezing symptoms. This might be
because of increased perception or reporting of
wheezing, or a genuine increase in minor
wheezing. The prevalence of diagnosed eczema
and hayfever in SheYeld has also increased
significantly, in keeping with other studies.2 4
This continuing increase in atopic disease may
also be contributing to the rising prevalence of
wheeze. An alternative explanation for the
increase in wheeze and asthma apparently
being confined to mild cases could be the
increased use of inhaled corticosteroids. This is
supported by the increase in reported
medication usage in asthmatic children. In a
population prevalence study in children aged
7.5–8.5 years from a single London borough,
the prevalence of frequent wheeze attacks was
unchanged between 1978 and 1991 while
markers of severe asthma fell over the same
period.5 The authors concluded that this find-
ing was due to an “improvement in treatment
received by wheezy children”. However, our
findings suggest that at least some of the
Table 1 Prevalence of asthma and asthma morbidity symptoms in 1991 and 1999
Survey year
1991 1999 % change (95% CI) p value
Wheeze in previous 12 months 771/4563 (17.0%) 932/4803 (19.4%) +2.51 (0.95 to 4.07) <0.01
Wheeze ever 1376/4564 (30.3%) 1720/4810 (35.8%) +5.66 (3.76 to 7.56) <0.001
Current asthma* 466/4539 (10.3%) 624/4800 (13.0%) +2.73 (1.44 to 4.03) <0.001
Asthma ever 811/4543 (17.9%) 1428/4806 (29.7%) +11.86 (10.16 to 13.57) <0.001
Wheeze attacks 1–3/year 438/4560 (9.6%) 551/4766 (11.6%) +1.96 (0.71 to 3.20) <0.001
Wheeze attacks >3/year 324/4560 (7.1%) 353/4766 (7.4%) +0.30 (–0.75 to 1.35) NSD
Nocturnal wheeze at least once a week 220/4548 (4.8%) 251/4757 (5.3%) +0.44 (–0.45 to 1.33) NSD
Nocturnal cough at least once a week 361/4435 (8.1%) 392/4784 (8.2%) +0.05 (–1.06 to 1.17) NSD
Frequent exertional wheeze or cough 174/4493 (3.9%) 217/4901 (4.4%) +0.55 (–0.25 to 1.36) NSD
Speech limiting wheeze in last year 136/4558 (3.0%) 125/4749 (2.6%) –0.4 (–1.04 to 0.30) NSD
Eczema ever 820/4523 (18.1%) 1497/4809 (31.1%) +13.0 (11.27 to 14.72) <0.001
Hayfever ever 554/4508 (12.3%) 787/4802 (16.4%) +4.1 (2.68 to 5.2) <0.001
Data are shown as number/denominator (%).
CI = confidence interval; NSD = no significant diVerence.
*Defined by a positive answer to the question “Does your child have asthma at present?”
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apparent increase may be due to changes in the
perception of minor wheezing symptoms.
A final point to be noted in our results is the
high use of asthma medication in children who
lack either a recent history of wheeze or a diag-
nosis of asthma. This suggests that asthma is
being overtreated or overdiagnosed in a signifi-
cant number of children and reinforces the need
to review and step down asthma treatment in
children when symptom control is adequate.
In conclusion, our results suggest an increase
in the prevalence of both diagnosed asthma
and current wheeze between 1991 and 1999 in
8–9 year old SheYeld children. This appears to
be due to the combination of an increase in
minor wheeze symptoms and a rise in diagnos-
tic labelling. We found no significant change in
asthma severity. Although this may be due in
part to an increase in prescription of anti-
inflammatory medication, the large number of
children without current wheeze who are
receiving asthma medication suggests that
there may be significant overtreatment of chil-
dren with such drugs.
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EVect of intravenous pamidronate on bone
mineral density in adults with cystic fibrosis
C S Haworth, P L Selby, J E Adams, E B Mawer, A W Horrocks, A K Webb
Abstract
Background—Low bone mineral density
(BMD) is prevalent in adults with cystic
fibrosis. The aim of this study was to
assess the eVect of intravenous pamidro-
nate on BMD in these subjects.
Methods—Patients were invited to par-
ticipate if they had a BMD Z score of –2 or
less in the lumbar spine, proximal femur,
or distal forearm. Patients were ran-
domised to receive either 30 mg intra-
venous pamidronate every 3 months + 1 g
calcium daily (pamidronate group) or 1 g
calcium daily (control group). All pancre-
atic insuYcient patients were prescribed
oral vitamin D supplements.
Results—After 6 months of treatment the
pamidronate group (n=13) showed a sig-
nificant increase in absolute BMD com-
pared with the control group (n=15) in the
lumbar spine (mean diVerence 5.8% (CI
2.7% to 8.9%)) and total hip (mean diVer-
ence 3.0% (CI 0.3% to 5.6%)). However,
the pamidronate group showed a reduc-
tion in BMD compared with the control
group in the distal forearm (mean diVer-
ence –1.7% (CI –3.7% to 0.3%)). The use of
pamidronate was associated with a high
incidence of bone pain in non-
corticosteroid treated individuals.
Conclusion—Intravenous pamidronate
increases axial BMD in adults with cystic
fibrosis, but the high incidence of bone
pain associated with this treatment might
limit its use.
(Thorax 2001;56:314–316)
Keywords: cystic fibrosis; bone mineral density; osteo-
porosis; pamidronate; bisphosphonates
Low bone mineral density (BMD) is prevalent
in adults with cystic fibrosis.1 2 Biochemical
and histomorphometric studies suggest that
osteoblastic activity is reduced and that osteo-
clastic activity is increased.3 4 As bisphospho-
nates are potent inhibitors of osteoclastic bone
resorption, they are a logical therapeutic choice
to treat adult cystic fibrosis patients with low
BMD. The aim of this study was to assess the
eVect of intravenous pamidronate on BMD in
adults with cystic fibrosis.
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